Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand

December 2, 2010 updated by: AstraZeneca

Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand

The purpose of this study is to determine the incidence of misuse, i.e., over-use and under-use, of Budesonide/formoterol for maintenance and reliever therapy in usual-care setting.

Study Overview

Status

Completed

Conditions

Asthma

Study Type

Observational

Enrollment (Anticipated)

1020

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Thailand
- - Buriram, Thailand
    - Research Site
  - Chanthaburi, Thailand
    - Research Site
  - Chiang Mai, Thailand
    - Research Site
  - Mahasarakham, Thailand
    - Research Site
  - Nakhon Phanom, Thailand
    - Research Site
  - Nakhon Srithammarat, Thailand
    - Research Site
  - Nakhonpathom, Thailand
    - Research Site
  - Phattalung, Thailand
    - Research Site
  - Phitsanulok, Thailand
    - Research Site
  - Rayong, Thailand
    - Research Site
  - Roi Et, Thailand
    - Research Site
  - Samutsakhon, Thailand
    - Research Site
  - Surat Thani, Thailand
    - Research Site
  - Trang, Thailand
    - Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient aged 12 years or older who established persistent asthma and currently treated with Symbicort SMART for 3 months or longer.

Description

Inclusion Criteria:

Established persistent asthma
Currently treated with Symbicort SMART for 3 months or longer

Exclusion Criteria:

currently participating or have participated in a study with an investigational compound within the last 30 days
current diagnosis of chronic obstructive pulmonary disease (COPD)
smoked more than 10 pack-year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of budesonide/formoterol use per patient Time Frame: On the survey date	On the survey date

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

Principal Investigator: Bandit Thinkhamrop, PhD., Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University
Principal Investigator: Watchara Boonsawat, MD, PhD, Department of Medicine, Faculty of Medicine, Khon Kaen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2009

Study Completion (Actual)

November 1, 2009

Study Registration Dates

First Submitted

December 1, 2008

First Submitted That Met QC Criteria